Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.
US-based autoimmune disease and cancer drug developer Abcuro has completed a $42m series A-1 round co-led by investment vehicles for pharmaceutical firm Sanofi and healthcare provider Mass General Brigham. Sanofi Ventures and Mass General Brigham Ventures were joined in the round by Pontifax Venture Capital, Hongsen Investment Group, RA Capital Management and Samsara BioCapital. Abcuro…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.